Harrow, Inc. (HROW) stock
Close on Nov 11, 2026Market cap $1.10BP/E –Yield –
Harrow, Inc. grew revenue 21.3% to $303.25M over the twelve months to Sep 30, 2026. Operating income fell 121.7% to -$6.03M, moving the operating margin from 11.1% to -2.0%. Free cash flow was -$20.35M, down 222.8% from a year earlier. At the latest close the market valued the company at $1.10B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.10B
- P/E ratio
- –
- Price to sales
- 3.63
- Price to book
- 37.72
- Dividend yield
- –
- Free cash flow yield
- -1.85%
Fundamentals
- Revenue
- $303.25M
- Net income
- -$28.49M
- EPS, diluted
- -$0.77
- Free cash flow
- -$20.35M
- Book value per share
- $0.76
- Diluted shares
- 39M
Trading
- Next earnings
- Mar 1, 2027 (estimated, after the close)
- Previous close
- $30.36
- Open
- $29.88
- Day's range
- $28.60 – $30.52
- Volume
- 979,492
- Average volume (20 days)
- 699,355
- Index membership
- Russell 2000 (since Jun 2023), Russell 3000 (since Aug 2023)
- Beta (5 years)
- 1.36
- 52-week range
- $25.76 – $54.85
- RSI (14 days)
- 50.4
- Volatility (1 year)
- 64.0%
- Relative volume
- 1.64×
- WACC
- 10.6%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2009, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | HROW | S&P 500 | Difference | HROW per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +0.0% | -2.4% | +2.4 pts | ||
| 3 months | -25.5% | -1.2% | −24.3 pts | ||
| Year to date | -40.1% | +12.3% | −52.4 pts | ||
| 1 year | -24.2% | +12.4% | −36.6 pts | ||
| 3 years | +129.0% | +78.8% | +50.2 pts | +31.8% | +21.4% |
| 5 years | +163.2% | +75.2% | +88.0 pts | +21.4% | +11.9% |
| 10 years | +1004.1% | +311.1% | +693.0 pts | +27.1% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Harrow filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Update
- Results
- Results
About Harrow
Pharmaceutical Preparations
Harrow, Inc. is an eye-care pharmaceutical company that specializes in the development, production, and commercialization of ophthalmic treatments and compounded medications. The company operates through two primary business segments: Branded and ImprimisRx. Its portfolio includes commercial ophthalmic therapies, notably VEVYE and IHEEZO, as well as specialized formulations. Harrow serves healthcare professionals, specialized clinics, hospitals, pharmacies, and patients requiring tailored pharmaceutical solutions.
Company profile, executives and historyHarrow stock: common questions
What is Harrow's stock price?
HROW closed at $29.37 on Nov 11, 2026, down 3.26% on the day. Over the past 52 weeks it traded between $25.76 and $54.85.
What is Harrow's market cap?
Harrow was worth $1.10B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is HROW's P/E ratio?
Harrow lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.77), so it has no meaningful P/E ratio.
How much revenue does Harrow make?
Harrow reported revenue of $303.25M for the twelve months to Sep 30, 2026, up 21.3% from a year earlier.
Does Harrow pay a dividend?
No. Harrow has not paid a cash dividend over the last twelve months.
When does Harrow report earnings next?
Harrow is expected to report Q4 FY2026 results on Mar 1, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has HROW stock performed over the past year?
Including dividends, HROW returned -24.2% over the past year, against +12.4% for the S&P 500.
How many HROW shares are sold short?
7M shares were sold short at the latest FINRA report, 22.06% of the float, or 14.1 days of average trading volume.
Who are Harrow's competitors?
Companies most similar to Harrow by business, industry and size include OPK, KMDA, ANIP, KPTI, MNKD.
See a number that looks wrong?